Geneva, May 7 -- International Clinical Trials Registry received information related to the study (ISRCTN14753723) titled 'A study to test the safety, tolerability and effect of ZI-MA4-1 for patients with locally advanced or metastatic solid malignancies' on May 1.
Study Type: Interventional
Study Design:
Allocation: N/A: single arm study
Masking: Open (masking not used)
Control: Uncontrolled
Assignment: Single
Purpose: Treatment
Primary Sponsor: Zelluna Immunotherapy AS
Condition:
Ovarian cancer, squamous non-small-cell lung cancer, synovial sarcoma, head and neck cancer.
Cancer
Intervention:
This is an open-label, first-in-human, Phase 1 dose-escalation study (3+3 design) evaluating the safety and tolerability of ZI-MA4-1, an a...